HOME >> BIOLOGY >> NEWS
Why passive smoking hinders healing

Being exposed to high levels of 'second-hand' smoke can reduce the speed at which wounds heal, leading to a lack of healing or greater levels of scarring. A study published in the journal BMC Cell Biology this week may begin to explain why: when cells are exposed to smoke, their ability to migrate towards the site of damage is compromised.

The study, carried out by researchers from University of California, Riverside, examined the effects of 'second-hand' smoke on fibroblasts, cells that play a major role in wound healing. They found that, among other things, exposure to smoke altered the arrangement of the cells' cytoskeleton increasing the cells' adhesive properties and thus reducing their motility.

The researchers write: "These effects can contribute to abnormal healing and may explain why people who are consistently exposed to 'second-hand' smoke suffer from slow healing and excessive scarring of wounds, much like smokers themselves."

The research team, led by Professor Manuela Martins-Green, bubbled smoke from the lit end of cigarettes through cell culture media to form a solution containing the major components of 'second-hand' smoke. They then diluted the 'smoky media' until the smoke components reached the levels found in the tissues of passive smokers.

When they added this media to fibroblast cells cultured in vitro, the researchers saw that the cells became more elongated and that they separated from one another. By studying components of the cytoskeleton in more detail the researchers saw that exposure to smoke increased the level of one particular cytoskeletal component, actin, inside the cell. It also increased the number of points at which the cell stuck to the Petri dish, sites that could be identified by the presence of 'focal adhesion plaques'.

In a separate experiment, the researchers showed that fibroblasts that had been cultured in the 'smoky medium' were less mobile than control cells.

During nor
'"/>

Contact: Gemma Bradley
press@biomedcentral.com
44-207-323-0323
BioMed Central
4-Apr-2004


Page: 1 2

Related biology news :

1. New study shows passive cigarette smoke at least doubles risk of cancer in cats
2. Household exposure to passive smoke depletes some vitamins in non-smokers
3. Fox Chase Cancer Center researchers identify significant smoking-induced genetic alteration
4. Doctors miss chances to help pregnant women quit smoking
5. Breastfeeding may compensate for harmful effects of smoking during pregnancy
6. New study tightens the link between smoking and early menopause
7. Benzene responsible for high percentage of leukemia deaths induced by smoking
8. Occupational disease associated with pneumatic tool use worsened by smoking
9. Study shows gene may boost smoking-related heart disease
10. Emphysema linked to smoking marijuana
11. University of Pittsburgh-led team finds biological reason for womens increased risk of smoking-related lung cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Why passive smoking hinders healing

(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... CT ., Aug. 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces it has joined The Smart Card Alliance and ... Smart Card Alliance and the Smart Card Alliance Latin ... visibility to industry peers and thought leaders promoting adoption ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
(Date:8/28/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: ... the development of autologous cell therapies, today reported ... 2015, corporate highlights, and near-term milestones.  The company,s ... www.sedar.com ,  www.edgar.com and at ... to launch its RCS-01 treatment for aging and ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas ... investment firms and animal health companies to hear from animal health companies with ... have also received licensing agreements or distribution contracts. This meeting is one ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and six-month periods ended June 30, 2015. Biorem,s complete second quarter ... ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended ... 2014 , 2015 , 2014 Revenue ... , 4,433 Gross profit , 1,656 , ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
Cached News: